← Back to Search

Physical Activity Intervention for Cognitive Function Post-Stem Cell Transplant (PROACTIVE Trial)

N/A
Recruiting
Led By Thuy Koll, MD
Research Sponsored by Thuy Koll MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will adapt and test an evidence-based physical activity intervention, The Community Health Activities Model Program for Seniors II (CHAMPS II), in the hematopoietic cell transplantation (HCT) setting for adults 60 years and older in order to improve cognitive function.

Who is the study for?
This trial is for older adults aged 60+ who have hematological malignancies like lymphoma or leukemia and are undergoing stem cell transplant. They must be able to walk a short distance, speak English, and consent to participate. Care-partners of these patients can also join if they meet similar criteria.
What is being tested?
The trial tests an adapted physical activity program called CHAMPS-II, designed to improve cognitive function in seniors post-stem cell transplant. Participants will engage in light to moderate exercises until Day 100 post-transplant compared with a wait-list control group.
What are the potential side effects?
Since the intervention involves physical activity, potential side effects may include typical exercise-related issues such as muscle soreness or fatigue. However, participants with severe reactions during initial assessments or those not cleared by physicians are excluded.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in executive function as measured by Trails A.
Change in executive function as measured by Trails B.
Change in executive function as measured by the Controlled Oral Word Association Test (COWAT).
+1 more
Secondary study objectives
Change in global cognitive function as measured by the Montreal Cognitive Assessment (MoCA).
Change in subjective memory as measured by the Neuro-Quality of Life (QOL) Cognition Function-Short Form.
Other study objectives
Change in endurance as measured by the 6-minute walk.
Change in functional ability as measured by the Short Performance Physical Battery (SPPB).
Change in performance of instrumental activities of daily living as measured by the Lawton Instrumental Activities of Daily Living (IADL).
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Adapted CHAMPS-II interventionExperimental Treatment1 Intervention
All participants in Aim 2 (preliminary testing) and Aim 3 (RCT) will participate in the CHAMPS-II physical activity program adapted to the HCT setting. Testing for outcome measures will be completed, and feedback on the intervention will be obtained via qualitative interviews from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members. Aim 3 participants will be randomized to either the immediate intervention (intervention then follow-up) or delayed intervention (wait period and then intervention).
Group II: Feedback for Preliminary AdaptationActive Control1 Intervention
Participants in Aim 1 will participate in qualitative interviews to obtain feedback on the CHAMPS-II intervention and survivorship education active control condition materials. Interviews will be with 1)adult participants 60+ years who have recently undergone HCT, 2)participants' care-partner, and 3)HCT team members.

Find a Location

Who is running the clinical trial?

Thuy Koll MDLead Sponsor
University of NebraskaLead Sponsor
555 Previous Clinical Trials
1,145,298 Total Patients Enrolled
38 Trials studying Lymphoma
1,414 Patients Enrolled for Lymphoma
Thuy Koll, MDPrincipal InvestigatorUniversity of Nebraska
1 Previous Clinical Trials
110 Total Patients Enrolled

Media Library

CHAMPS-II adapted to adults 60+ years in HCT setting Clinical Trial Eligibility Overview. Trial Name: NCT04898790 — N/A
Lymphoma Research Study Groups: Adapted CHAMPS-II intervention, Feedback for Preliminary Adaptation
Lymphoma Clinical Trial 2023: CHAMPS-II adapted to adults 60+ years in HCT setting Highlights & Side Effects. Trial Name: NCT04898790 — N/A
CHAMPS-II adapted to adults 60+ years in HCT setting 2023 Treatment Timeline for Medical Study. Trial Name: NCT04898790 — N/A
~28 spots leftby Jun 2026